Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Medicalgorithmics S.A. (MDG.WA)
Warsaw, PL
Established in 2005 and headquartered in Warsaw, Poland, Medicalgorithmics S.A. is a prominent provider of cardiac diagnostic solutions, serving markets in Poland, the United States, and globally. The company offers an array of advanced products, including PocketECG, a comprehensive diagnostic system for arrhythmia detection that furnishes detailed ECG signals, data analysis, and exhaustive reports. Another key offering is PocketECG CRS, specifically designed for monitoring patients during cardiac rehabilitation. Its technological portfolio also encompasses ECG TechBot, a software program that utilizes algorithms for the automated analysis and interpretation of ECG signals, and PatchECG, a device enabling single-channel, offline heart monitoring. Additionally, PocketECG IV enhances the core PocketECG device by enabling continuous ECG signal transmission via LTE connectivity. Beyond its innovative devices, Medicalgorithmics S.A. delivers services in information technology, biotechnology, ECG monitoring, and scientific research and development, alongside manufacturing and distributing electro-medical equipment.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.42% | -2.05% | +8.33% | -11.59% | -10.76% | -16.62% | +9.16% | +40.89% | -4.67% | -89.79% | +39.58% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+29.1% ★ Q1'26: +51.2% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+27.8% Q1'26: +47.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-15.6% Q1'26: -25.9% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-37.0% Q1'26: -9.6% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-13.6% Q1'26: -4.6% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-3.30× Q1'26: 14.39× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
49.33M
est: 49.54M (-0.4%)
|
127.92M
est: 135.40M (-5.5%)
|
203.35M
est: 135.40M (+50.2%)
|
199.40M
est: 202.05M (-1.3%)
|
173.87M
est: 244.00M (-28.7%)
|
111.73M
est: 284.00M (-60.7%)
|
48.35M
est: 317.00M (-84.7%)
|
62.72M
est: 337.30M (-81.4%)
|
43.10M
est: 39.90M (+8.0%)
|
24.00M
est: 26.70M (-10.1%)
|
30.99M
est: 31.08M (-0.3%)
|
48.87M
42.09M – 55.65M
+57.2% YoY
|
70.26M
53.95M – 86.57M
+43.8% YoY
|
98.92M
97.40M – 100.44M
+40.8% YoY
|
67.20M
57.87M – 76.53M
-32.1% YoY
|
| EBITDA |
18.92M
est: -2.22M (+950.6%)
|
52.49M
est: -6.08M (+963.2%)
|
53.55M
est: -6.08M (+980.7%)
|
37.02M
est: -9.07M (+508.0%)
|
18.38M
est: -10.96M (+267.7%)
|
-23.04M
est: -12.75M (-80.6%)
|
-2.20M
est: -14.24M (+84.5%)
|
29.76M
est: -15.15M (+296.4%)
|
2.24M
est: -1.79M (+224.7%)
|
-11.98M
est: -1.28M (-839.5%)
|
-6.83M
est: -1.48M (-360.1%)
|
-2.33M
-2.66M – -2.01M
-57.2% YoY
|
-3.36M
-4.13M – -2.58M
-43.8% YoY
|
-4.72M
-4.80M – -4.65M
-40.8% YoY
|
-3.21M
-3.65M – -2.76M
+32.1% YoY
|
| EBIT |
17.31M
est: -7.20M (+340.3%)
|
48.36M
est: -19.69M (+345.6%)
|
41.82M
est: -19.69M (+312.4%)
|
24.72M
est: -29.38M (+184.2%)
|
-572.0K
est: -35.48M (+98.4%)
|
-38.99M
est: -41.30M (+5.6%)
|
-6.40M
est: -46.09M (+86.1%)
|
25.53M
est: -49.05M (+152.1%)
|
-130.0K
est: -5.80M (+97.8%)
|
-15.61M
est: -4.00M (-290.5%)
|
-11.47M
est: -4.65M (-146.4%)
|
-7.32M
-8.33M – -6.30M
-57.2% YoY
|
-10.52M
-12.96M – -8.08M
-43.8% YoY
|
-14.81M
-15.04M – -14.59M
-40.8% YoY
|
-10.06M
-11.46M – -8.67M
+32.1% YoY
|
| Net Income |
13.93M
est: 60.30M (-76.9%)
|
40.11M
est: 117.15M (-65.8%)
|
25.54M
est: 117.15M (-78.2%)
|
14.42M
est: 74.05M (-80.5%)
|
-299.0K
est: 59.32M (-100.5%)
|
-12.92M
est: 67.28M (-119.2%)
|
-180.64M
est: 75.44M (-339.4%)
|
-11.86M
est: 142.73M (-108.3%)
|
-578.0K
est: 995.3K (-158.1%)
|
-16.08M
est: -13.45M (-19.6%)
|
-11.68M
est: -11.01M (-6.1%)
|
962.1K
788.5K – 1.14M
+108.7% YoY
|
4.35M
3.18M – 5.51M
+351.7% YoY
|
6.59M
3.63M – 19.00M
+51.6% YoY
|
3.48M
2.85M – 4.11M
-47.1% YoY
|
| SGA |
12.19M
est: 14.33M (-14.9%)
|
35.19M
est: 39.17M (-10.2%)
|
23.87M
est: 39.17M (-39.1%)
|
26.33M
est: 58.44M (-54.9%)
|
33.67M
est: 70.58M (-52.3%)
|
25.79M
est: 82.15M (-68.6%)
|
32.29M
est: 91.69M (-64.8%)
|
5.07M
est: 97.57M (-94.8%)
|
13.36M
est: 11.54M (+15.8%)
|
3.76M
est: 7.37M (-49.0%)
|
5.10M
est: 8.58M (-40.5%)
|
13.49M
11.62M – 15.36M
+57.2% YoY
|
19.39M
14.89M – 23.89M
+43.8% YoY
|
27.30M
26.88M – 27.72M
+40.8% YoY
|
18.55M
15.97M – 21.12M
-32.1% YoY
|
| EPS |
3.86
est: 6.06 (-36.3%)
|
11.12
est: 11.77 (-5.5%)
|
7.08
est: 11.77 (-39.8%)
|
4.00
est: 7.44 (-46.2%)
|
-0.08
est: 5.96 (-101.4%)
|
-3.12
est: 6.76 (-146.2%)
|
-39.73
est: 7.58 (-624.1%)
|
-2.08
est: 14.34 (-114.5%)
|
-0.11
est: 0.10 (-210.0%)
|
-1.62
est: -1.30 (-24.6%)
|
-1.17
est: -1.11 (-5.7%)
|
0.10
0.08 – 0.11
+108.7% YoY
|
0.44
0.32 – 0.55
+351.7% YoY
|
1.14
0.36 – 1.91
+160.3% YoY
|
0.35
0.29 – 0.41
-69.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 21.3K | 0.39% |
| 2 | State Street SPDR Portfolio Europe ETF SPEU | 0.00% | 893.72 | 0.07% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Catalina Barrero Guzman | Marketing Manager | — | female |
| Jaroslaw Jerzakowski | Chief Operating Officer | — | male |
| Katarzyna Perzak | Director of Investor Relations | — | — |
| Krzysztof Siemionow | President of the Management Board & Chief Executive Officer | — | — |
| Linda Johnson | Chief Scientific Officer | — | female |
| Michal Zapora | Chief Financial Officer & Member of the Management Board | — | male |
| Przemyslaw Tadla | Chief Technology Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MDG.WA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
